{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:57:32Z","timestamp":1781081852734,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation","award":["TCRD-TPE-115-17"],"award-info":[{"award-number":["TCRD-TPE-115-17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00228-026-04072-0","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T02:18:53Z","timestamp":1778120333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on lipid profiles in patients with chronic kidney disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Yun-Hui","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Han","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Rong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"4072_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.06.006","volume":"109","author":"KDIGO","year":"2026","unstructured":"KDIGO (2026) 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD). Kidney Int 109:S1-s99","journal-title":"Kidney Int"},{"key":"4072_CR2","doi-asserted-by":"publisher","first-page":"sfad143","DOI":"10.1093\/ckj\/sfad143","volume":"17","author":"R Minutolo","year":"2024","unstructured":"Minutolo R, Liberti ME, Simeon V, Sasso FC, Borrelli S, De Nicola L et al (2024) Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials. Clin Kidney J 17:sfad143","journal-title":"Clin Kidney J"},{"key":"4072_CR3","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s40265-022-01783-3","volume":"82","author":"F Locatelli","year":"2022","unstructured":"Locatelli F, Minutolo R, De Nicola L, Del Vecchio L (2022) Evolving strategies in the treatment of anaemia in chronic kidney disease: the HIF-prolyl hydroxylase inhibitors. Drugs 82:1565\u201389","journal-title":"Drugs"},{"key":"4072_CR4","doi-asserted-by":"publisher","first-page":"9382","DOI":"10.1074\/jbc.M117.788562","volume":"292","author":"S Hwang","year":"2017","unstructured":"Hwang S, Nguyen AD, Jo Y, Engelking LJ, Brugarolas J, DeBose-Boyd RA (2017) Hypoxia-inducible factor 1\u03b1 activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver. J Biol Chem 292:9382\u20139393","journal-title":"J Biol Chem"},{"issue":"Suppl 1","key":"4072_CR5","first-page":"S110","volume":"21","author":"VH Haase","year":"2017","unstructured":"Haase VH (2017) HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism. Hemodial Int 21(Suppl 1):S110\u2013S124","journal-title":"Hemodial Int"},{"key":"4072_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ki.2011.223","volume":"80","author":"CA Herzog","year":"2011","unstructured":"Herzog CA, Asinger RW, Berger AK, Charytan DM, D\u00edez J, Hart RG et al (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80:572\u201386","journal-title":"Kidney Int"},{"key":"4072_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Peng X, Lin H, Yin A, Hao L et al (2019) Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 381:1001\u201310","journal-title":"N Engl J Med"},{"key":"4072_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2460726","volume":"47","author":"T Xu","year":"2025","unstructured":"Xu T, Ruan Y, Liu N, Wang Y, Zang X, Ma Y et al (2025) Effect of Roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia. Ren Fail 47:2460726","journal-title":"Ren Fail"},{"key":"4072_CR9","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000523961","volume":"53","author":"D Agrawal","year":"2022","unstructured":"Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V et al (2022) Desidustat in anemia due to non-dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-ND). Am J Nephrol 53:352\u201360","journal-title":"Am J Nephrol"},{"key":"4072_CR10","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","volume":"39","author":"S Stoumpos","year":"2024","unstructured":"Stoumpos S, Crowe K, Sarafidis P, Barratt J, Bolignano D, Del Vecchio L et al (2024) Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association. Nephrol Dial Transplant 39:1710\u201330","journal-title":"Nephrol Dial Transplant"},{"key":"4072_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1159\/000518071","volume":"52","author":"H Yamamoto","year":"2021","unstructured":"Yamamoto H, Nobori K, Matsuda Y, Hayashi Y, Hayasaki T, Akizawa T (2021) Efficacy and safety of Molidustat for anemia in ESA-naive nondialysis patients: a randomized, phase 3 trial. Am J Nephrol 52:871\u201383","journal-title":"Am J Nephrol"},{"key":"4072_CR12","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.ajkd.2022.09.014","volume":"81","author":"Q Zheng","year":"2023","unstructured":"Zheng Q, Wang Y, Yang H, Sun L, Zhang P, Zhang X et al (2023) Cardiac and kidney adverse effects of HIF prolyl-hydroxylase inhibitors for anemia in patients with CKD not receiving dialysis: a systematic review and meta-analysis. Am J Kidney Dis 81:434\u201345.e1","journal-title":"Am J Kidney Dis"},{"key":"4072_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300189","volume":"3","author":"JT Ha","year":"2024","unstructured":"Ha JT, Hiremath S, Jun M, Green SC, Wheeler DC, Coyne DW et al (2024) Hypoxia-inducible factor prolyl hydroxylase inhibitors in kidney disease. NEJM Evid 3:EVIDoa2300189","journal-title":"NEJM Evid"},{"key":"4072_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"4072_CR15","unstructured":"Higgins JTJ, Chandler J, Cumpston M, Li T, Page MJ et al (eds) (2024) (s). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, Available from www.cochrane.org\/handbook"},{"key":"4072_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343:d5928","journal-title":"BMJ"},{"key":"4072_CR17","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560","journal-title":"BMJ"},{"key":"4072_CR18","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL et al (2021) Daprodustat for the treatment of anemia in patients not undergoing dialysis. N Engl J Med 385:2313\u201324","journal-title":"N Engl J Med"},{"key":"4072_CR19","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","volume":"385","author":"AK Singh","year":"2021","unstructured":"Singh AK, Carroll K, Perkovic V, Solomon S, Jha V, Johansen KL et al (2021) Daprodustat for the treatment of anemia in patients undergoing dialysis. N Engl J Med 385:2325\u201335","journal-title":"N Engl J Med"},{"key":"4072_CR20","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.jjcc.2025.09.011","volume":"86","author":"YS Singh","year":"2025","unstructured":"Singh YS, Matsue Y, Iso T, Fujimoto Y, Yanagisawa N, Shitara J et al (2025) Daprodustat for patients with heart failure and renal anemia: a pilot multicenter, open-label, randomized controlled study. J Cardiol 86:592\u20138","journal-title":"J Cardiol"},{"key":"4072_CR21","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","volume":"67","author":"R Provenzano","year":"2016","unstructured":"Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P et al (2016) Roxadustat (FG-4592) versus Epoetin Alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67:912\u201324","journal-title":"Am J Kidney Dis"},{"key":"4072_CR22","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/ndt\/gfaa060","volume":"36","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Farag YMK, de Goma E, Luo W, Vargo D, Khawaja Z (2021) Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized phase 2 trials in Japanese patients. Nephrol Dial Transplant 36:1244\u201352","journal-title":"Nephrol Dial Transplant"},{"key":"4072_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000513103","volume":"52","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Hamano T, Akizawa T, Tsubakihara Y, Nagai R, Okuda N et al (2021) Daprodustat compared with Epoetin Beta Pegol for anemia in Japanese patients not on dialysis: a 52-week randomized open-label phase 3 trial. Am J Nephrol 52:26\u201335","journal-title":"Am J Nephrol"},{"key":"4072_CR24","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1093\/ndt\/gfab191","volume":"36","author":"J Barratt","year":"2021","unstructured":"Barratt J, Andric B, Tataradze A, Schomig M, Reusch M, Valluri U et al (2021) Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant 36:1616\u201328","journal-title":"Nephrol Dial Transplant"},{"key":"4072_CR25","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","volume":"6","author":"C Charytan","year":"2021","unstructured":"Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL et al (2021) A randomized trial of Roxadustat in anemia of kidney failure: SIERRAS study. Kidney Int Rep 6:1829\u201339","journal-title":"Kidney Int Rep"},{"key":"4072_CR26","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","volume":"381","author":"N Chen","year":"2019","unstructured":"Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C et al (2019) Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 381:1011\u201322","journal-title":"N Engl J Med"},{"key":"4072_CR27","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","volume":"32","author":"N Chen","year":"2017","unstructured":"Chen N, Qian J, Chen J, Yu X, Mei C, Hao C et al (2017) Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 32:1373\u201386","journal-title":"Nephrol Dial Transplant"},{"key":"4072_CR28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ekir.2020.11.034","volume":"6","author":"DW Coyne","year":"2021","unstructured":"Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA et al (2021) Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep 6:624\u201335","journal-title":"Kidney Int Rep"},{"key":"4072_CR29","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","volume":"38","author":"B Csiky","year":"2021","unstructured":"Csiky B, Schomig M, Esposito C, Barratt J, Reusch M, Valluri U et al (2021) Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: A European phase 3, randomized, open-label, active-controlled study (PYRENEES). Adv Ther 38:5361\u201380","journal-title":"Adv Ther"},{"key":"4072_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1681\/ASN.2020081150","volume":"32","author":"S Fishbane","year":"2021","unstructured":"Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L et al (2021) Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study. J Am Soc Nephrol 32:737\u201355","journal-title":"J Am Soc Nephrol"},{"key":"4072_CR31","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2020111638","volume":"33","author":"S Fishbane","year":"2022","unstructured":"Fishbane S, Pollock CA, El-Shahawy M, Escudero ET, Rastogi A, Van BP et al (2022) Roxadustat versus Epoetin Alfa for treating anemia in patients with chronic kidney disease on dialysis: Results from the randomized phase 3 ROCKIES study. J Am Soc Nephrol 33:850\u201366","journal-title":"J Am Soc Nephrol"},{"key":"4072_CR32","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1159\/000523949","volume":"53","author":"S Gang","year":"2022","unstructured":"Gang S, Khetan P, Varade D, Chinta VR, Mavani S, Gupta U et al (2022) Desidustat in anemia due to dialysis-dependent chronic kidney disease: A phase 3 study (DREAM-D). Am J Nephrol 53:343\u201351","journal-title":"Am J Nephrol"},{"key":"4072_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","volume":"121","author":"YP Hou","year":"2022","unstructured":"Hou YP, Mao XY, Wang C, Xu ZH, Bu ZH, Xu M et al (2022) Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial. J Formos Med Assoc 121:529\u201338","journal-title":"J Formos Med Assoc"},{"key":"4072_CR34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2215\/CJN.02510218","volume":"14","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T (2019) Effects of Molidustat in the treatment of anemia in CKD. Clin J Am Soc Nephrol 14:28\u201339","journal-title":"Clin J Am Soc Nephrol"},{"key":"4072_CR35","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1159\/000500232","volume":"49","author":"DV Parmar","year":"2019","unstructured":"Parmar DV, Kansagra KA, Patel JC, Joshi SN, Sharma NS, Shelat AD et al (2019) Outcomes of Desidustat treatment in people with anemia and chronic kidney disease: A phase 2 study. Am J Nephrol 49:470\u20138","journal-title":"Am J Nephrol"},{"key":"4072_CR36","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","volume":"36","author":"R Provenzano","year":"2021","unstructured":"Provenzano R, Shutov E, Eremeeva L, Korneyeva S, Poole L, Saha G et al (2021) Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant 36:1717\u201330","journal-title":"Nephrol Dial Transplant"},{"key":"4072_CR37","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1093\/ndt\/gfab057","volume":"36","author":"E Shutov","year":"2021","unstructured":"Shutov E, Sulowicz W, Esposito C, Tataradze A, Andric B, Reusch M et al (2021) Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, double-blind, placebo-controlled study (ALPS). Nephrol Dial Transplant 36:1629\u201339","journal-title":"Nephrol Dial Transplant"},{"key":"4072_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.664258","volume":"9","author":"JAF Demandt","year":"2021","unstructured":"Demandt JAF, van Kuijk K, Theelen TL, Marsch E, Heffron SP, Fisher EA et al (2021) Whole-body prolyl hydroxylase domain (PHD) 3 deficiency increased plasma lipids and hematocrit without impacting plaque size in low-density lipoprotein receptor knockout mice. Front Cell Dev Biol 9:664258","journal-title":"Front Cell Dev Biol"},{"key":"4072_CR39","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1093\/eurheartj\/ehw156","volume":"37","author":"E Marsch","year":"2016","unstructured":"Marsch E, Demandt JA, Theelen TL, Tullemans BM, Wouters K, Boon MR et al (2016) Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia. Eur Heart J 37:2993\u20137","journal-title":"Eur Heart J"},{"key":"4072_CR40","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1161\/ATVBAHA.115.307136","volume":"36","author":"L Rahtu-Korpela","year":"2016","unstructured":"Rahtu-Korpela L, M\u00e4\u00e4tt\u00e4 J, Dimova EY, H\u00f6rkk\u00f6 S, Gylling H, Walkinshaw G et al (2016) Hypoxia-inducible factor prolyl 4-hydroxylase-2 inhibition protects against development of atherosclerosis. Arterioscler Thromb Vasc Biol 36:608\u201317","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4072_CR41","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1042\/BJ20111377","volume":"441","author":"GM Shen","year":"2012","unstructured":"Shen GM, Zhao YZ, Chen MT, Zhang FL, Liu XL, Wang Y et al (2012) Hypoxia-inducible factor-1 (HIF-1) promotes LDL and VLDL uptake through inducing VLDLR under hypoxia. Biochem J 441:675\u2013683","journal-title":"Biochem J"},{"key":"4072_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202400504","volume":"19","author":"TP Corner","year":"2024","unstructured":"Corner TP, Salah E, Tumber A, Kaur S, Nakashima Y, Allen MD et al (2024) Crystallographic and selectivity studies on the approved HIF prolyl hydroxylase inhibitors Desidustat and Enarodustat. ChemMedChem 19:e202400504","journal-title":"ChemMedChem"},{"key":"4072_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.116832","volume":"483","author":"VJ Patel","year":"2024","unstructured":"Patel VJ, Joharapurkar A, Kshirsagar SG, Patel MS, Savsani HH, Dodiya HS et al (2024) HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia. Toxicol Appl Pharmacol 483:116832","journal-title":"Toxicol Appl Pharmacol"},{"key":"4072_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fneph.2024.1459425","volume":"4","author":"A Joharapurkar","year":"2024","unstructured":"Joharapurkar A, Pandya V, Patel H, Jain M, Desai R (2024) Desidustat: a novel PHD inhibitor for the treatment of CKD-induced anemia. Front Nephrol 4:1459425","journal-title":"Front Nephrol"},{"key":"4072_CR45","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.isci.2019.10.002","volume":"20","author":"B Yao","year":"2019","unstructured":"Yao B, Wei Y, Zhang S, Tian S, Xu S, Wang R et al (2019) Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance. iScience 20:489\u201396","journal-title":"iScience"},{"key":"4072_CR46","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/MOL.0b013e3283402e9c","volume":"21","author":"B Angelin","year":"2010","unstructured":"Angelin B, Rudling M (2010) Lipid lowering with thyroid hormone and thyromimetics. Curr Opin Lipidol 21:499\u2013506","journal-title":"Curr Opin Lipidol"},{"key":"4072_CR47","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1093\/ndt\/gfad017","volume":"38","author":"Y Cheng","year":"2023","unstructured":"Cheng Y, Xiang Q, Cao T, Tang F, Chen J, Qi D et al (2023) Suppression of thyroid profile during Roxadustat treatment in chronic kidney disease patients. Nephrol Dial Transplant 38:1567\u201370","journal-title":"Nephrol Dial Transplant"},{"key":"4072_CR48","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1210\/clinem\/dgad483","volume":"109","author":"T Haraguchi","year":"2023","unstructured":"Haraguchi T, Hamamoto Y, Kuwata H, Yamazaki Y, Nakatani S, Hyo T et al (2023) Effect of Roxadustat on thyroid function in patients with renal anemia. J Clin Endocrinol Metab 109:e69\u2013e75","journal-title":"J Clin Endocrinol Metab"},{"key":"4072_CR49","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2199093","volume":"45","author":"X Zheng","year":"2023","unstructured":"Zheng X, Jin Y, Xu T, Xu H, Zhu S (2023) Thyroid function analysis after Roxadustat or Erythropoietin treatment in patients with renal anemia: a cohort study. Ren Fail 45:2199093","journal-title":"Ren Fail"},{"key":"4072_CR50","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.7150\/ijms.97599","volume":"21","author":"N Li","year":"2024","unstructured":"Li N, Cui W, Mu D, Shi X, Gao L, Liu S et al (2024) Effects of Roxadustat on thyroid hormone levels and blood lipid metabolism in patients undergoing hemodialysis: a retrospective study. Int J Med Sci 21:1806\u201313","journal-title":"Int J Med Sci"},{"key":"4072_CR51","doi-asserted-by":"publisher","first-page":"3e","DOI":"10.1016\/j.amjcard.2009.09.013","volume":"104","author":"P Deedwania","year":"2009","unstructured":"Deedwania P, Singh V, Davidson MH (2009) Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials. Am J Cardiol 104:3e\u20139e","journal-title":"Am J Cardiol"},{"key":"4072_CR52","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/ije\/dyad011","volume":"52","author":"JG M\u00f8rland","year":"2023","unstructured":"M\u00f8rland JG, Magnus P, Vollset SE, Leon DA, Selmer R, Tverdal A (2023) Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20\u201379 years. Int J Epidemiol 52:1257\u20131267","journal-title":"Int J Epidemiol"},{"key":"4072_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001423","author":"RS Blumenthal","year":"2026","unstructured":"Blumenthal RS, Morris PB, Gaudino M, Johnson HM, Anderson TS, Bittner VA et al (2026) 2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. https:\/\/doi.org\/10.1161\/CIR.0000000000001423","journal-title":"Circulation"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04072-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04072-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T08:01:56Z","timestamp":1781078516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04072-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4072"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04072-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}